Clinical Trial Update: A Study of RO4917838 (Bitopertin) in Patients With Sub-optimally Controlled Symptoms of Schizophrenia (WN25306) [Phase 3]

View source ↗

Summary

Phase 3 trial of Bitopertin (RO4917838) in schizophrenia has completed. The update reports the study status without detailing results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia

Drugs mentioned

• Bitopertin (RO4917838) (Bitopertin)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Schizophrenia | Phase 3 | Status: COMPLETED